Ezygo Tablet

Ezygo is indicated in the following conditions-

• Constipation of any etiology
• Relief from prolonged & recurrent constipation
• Bowel clearance before surgery, childbirth or radiological investigations.

Sodium Picosulfate is a triarylmethane group derivative stimulant laxative. After oral administration it is activated by the colonic bacteria and acts locally in the colon. The active form then stimulates the nerve endings of the intestinal wall and results in colonic peristalsis with promotion of accumulation of water and electrolytes in the colonic lumen. This results in stimulation of defecation, reduction of transit time and softening of the stool. Stimulation of the rectum causes increased motility and a feeling of rectal fullness. The rectal effect may help to restore the "call to stool".

For oral administration. The following dosages are recommended to be taken at night to produce evacuation the following morning. It is recommended to start with the lowest dose. The dose may be adjusted up to the maximum recommended dose to produce regular stools. The maximum recommended daily dose should not be exceeded:

10 mg tablet dose:

• Adults and children over 10 years of age: 5-10 mg per day.
• Children aged 4-10 years: 2.5-5 mg per day.

Oral Solution (5 mg/5 ml) dose:

• Adults and children over 10 years of age: 5-10 ml or one to two teaspoonful per day.
• Children aged 4-10 years: 2.5-5 ml or half to one teaspoonful per day.
• Children from One month to 4 years of age: 0.25 ml/kg body weight per day.

Concentrated Oral Solution (7.5 mg/ml) dose:

• Adults and children over 10 years of age: 0.67-1.33 ml per day.
• Children aged 4-10 years: 0.33-0.67 ml per day.

The concomitant use of diuretics or adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses are taken. Concurrent administration of antibiotics may reduce the laxative action of Ezygo.

Ileus or intestinal obstruction, severe painful and/or feverish acute abdominal conditions (e.g. appendicitis) potentially associated with nausea and vomiting, acute inflammatory bowel diseases, severe dehydration, known hypersensitivity to Sodium Picosulfate or any other component of the product.

Hypersensitivity, dizziness, syncope, vasovagal response, gastrointestinal disorders, diarrhea, abdominal pain and abdominal cramps, nausea, vomiting.

There are no reports of undesirable or damaging effects during pregnancy or to the foetus attributable to the use of this product. Use of the drug should be avoided during the first trimester. Clinical data show that neither the active moiety of sodium Picosulfate (BHPM or bis-(p hydroxyphenyl)-pyridyl-2-methane) nor its glucuronides are excreted into the milk of healthy lactating females.

Prolonged excessive use may lead to fluid and electrolyte imbalance and hypokalemia. Harmful for those suffering from alcoholism. To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy.

Laxatives when taken in chronic overdosage may cause chronic diarrhea, abdominal pain, hypokalemia, secondary hyperaldosteronism, and renal calculi. Renal tubular damage, metabolic alkalosis, and muscle weakness secondary to hypokalemia have also been described in association with chronic laxative abuse.

Stimulant Laxative

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Molecular Formula :	C18H15NNa2O9S2
Chemical Structure :